论文部分内容阅读
为了确定晚期非小细胞肺癌患者(NSCLC)临床应用顺铂或卡铂治疗是否等效,日本 Okayama 大学医学院的 Hotta K 等人近日开展一项分别以顺铂或卡铂为基础的化疗随机对比研究,以便对患者预后疗效进行 meta 分析。研究人员们首先对卡铂替换顺铂治疗晚期非小细胞肺癌的研究文献进行检索分析,然后基于试验内容、方法学质量以及相关数据对其化疗效果进行
To determine whether the clinical use of cisplatin or carboplatin for advanced non-small cell lung cancer (NSCLC) is equivalent, Hotta K et al. At Okayama University School of Medicine in Japan recently conducted a randomized comparison of either cisplatin or carboplatin-based chemotherapy Study, in order to conduct a meta-analysis of the prognosis of patients. Researchers first conducted a search and analysis of the research literature on the use of carboplatin in the replacement of Cisplatin in the treatment of advanced non-small cell lung cancer. Then, based on the contents of the experiment, the quality of the methodologies and relevant data, the chemotherapeutic effect